Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Winston

Showing results (161-170 of 241) with videos related to

Pageof 25
Sort By:
The Lancet. HIV|September 16, 2024
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort studySam Nightingale, Anna J Dreyer, Kevin G F Thomas, et al.
International Journal of STD & AIDS|December 5, 2019
Cognitive function and drivers of cognitive impairment in a European and a Korean cohort of people living with HIVDavide De Francesco, Jae-Phil Choi, Jun Y Choi, et al.
AIDS (London, England)|July 2, 2019
Risk factors and impact of patterns of co-occurring comorbidities in people living with HIVDavide De Francesco, Jonathan Underwood, Emmanouil Bagkeris, et al.
Plos One|May 7, 2013
Neurocognitive function in HIV infected patients on antiretroviral therapyAlan Winston, Alejandro Arenas-Pinto, Wolfgang Stöhr, et al.
HIV Medicine|April 16, 2026
Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ARTMerle Henderson, Peter Dutey-Magni, Carolina Herrera, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 27, 2020
Associations Between Widespread Pain and Sleep Quality in People With HIVCaroline A Sabin, Richard Harding, Nicki Doyle, et al.
Elife|August 13, 2021
Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapyAlexander O Pasternak, Jelmer Vroom, Neeltje A Kootstra, et al.
Eclinicalmedicine|February 16, 2024
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
The Lancet. HIV|October 2, 2015
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialNicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Pageof 25

Showing results (161-170 of 241) with videos related to

Sort By:
Pageof 25
The Lancet. HIV|September 16, 2024
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort studySam Nightingale, Anna J Dreyer, Kevin G F Thomas, et al.
International Journal of STD & AIDS|December 5, 2019
Cognitive function and drivers of cognitive impairment in a European and a Korean cohort of people living with HIVDavide De Francesco, Jae-Phil Choi, Jun Y Choi, et al.
AIDS (London, England)|July 2, 2019
Risk factors and impact of patterns of co-occurring comorbidities in people living with HIVDavide De Francesco, Jonathan Underwood, Emmanouil Bagkeris, et al.
Plos One|May 7, 2013
Neurocognitive function in HIV infected patients on antiretroviral therapyAlan Winston, Alejandro Arenas-Pinto, Wolfgang Stöhr, et al.
HIV Medicine|April 16, 2026
Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ARTMerle Henderson, Peter Dutey-Magni, Carolina Herrera, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 27, 2020
Associations Between Widespread Pain and Sleep Quality in People With HIVCaroline A Sabin, Richard Harding, Nicki Doyle, et al.
Elife|August 13, 2021
Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapyAlexander O Pasternak, Jelmer Vroom, Neeltje A Kootstra, et al.
Eclinicalmedicine|February 16, 2024
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
The Lancet. HIV|October 2, 2015
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialNicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Pageof 25